Advisory Board

Webinar

Astera and Vantris are disrupting oncology with condition-based bundles

Tuesday, August 25, 2026
5:00 PM-6:00 PM

About the webinar

To date, most value-based care (VBC) efforts have focused on primary care, even though specialty care drives the bulk of healthcare spending. We've identified leading organizations that have overcame long-standing barriers to engage specialists in VBC. Join Advisory Board experts in a conversation with the CEO of Astera Cancer Care, Dr. Edward Licitra, and the CCO of Vantris Oncology, Joe O'Hara. We'll discuss how these two organizations together have achieved success building and scaling a value-based model in oncology care.

Things you'll learn:

  • How Astera and Vantris define, measure, and operationalize value in oncology care
  • Lessons leaders learned from building and scaling a condition-based bundles in a high-cost specialty

You must register to join the session or access the materials or recording.

Speakers

Take a look at our speakers scheduled for this event

Rhea Jain

Senior research analyst, Value-based care research
Advisory Board

Edward J . Licitra, MD, PhD

Medical Oncology, Hematology, Chief Executive Officer
Astera Cancer Care

Joe O’Hara

Chief Commercial Officer
Vantris Oncology

Registration

* 

What's your primary purpose for participating in this event?

This question is required.
* 

By clicking submit below I agree and consent to Advisory Board collecting, using, processing, and storing my personal information including my name and email so that Advisory Board may contact me in relation to the services that I receive from Advisory Board. I acknowledge that my personal data will be stored within the United States of America which may not provide the same level of protection as my home country. This consent is valid unless I have opted out or withdrawn consent. I understand that consent may be withdrawn at any time by contacting Optum at information_governance@optum.com. Advisory Board is a subsidiary of Optum. All Advisory Board research, expert perspectives, and recommendations remain independent.

Advisory Board